Despite insider buying and a roughly 7.4% uptick in the stock, external signals are mixed: Weiss Ratings initiated coverage with a “Sell (D-)” and recent public-offering closings reporting ~$35M-$40.25M could boost liquidity but may imply shareholder dilution.
Biosig Technologies, Inc. (NASDAQ:STEX – Get Free Report) major shareholder Frank Giustra purchased 1,000,000 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The stock was acquired at an average cost of $3.00 per share, with a total value of $3,000,000.00. Following the transaction, the insider directly owned 1,178,205 shares of the company’s stock, valued at approximately $3,534,615. This represents a 561.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Biosig Technologies Stock Up 7.4%
Shares of STEX opened at $3.65 on Wednesday. Biosig Technologies, Inc. has a 1 year low of $0.40 and a 1 year high of $14.11.
Key Headlines Impacting Biosig Technologies
Here are the key news stories impacting Biosig Technologies this week:
* Positive Sentiment: Major shareholder Frank Giustra bought 1,000,000 shares at $3.00 (≈$3.0M), increasing his direct stake to 1,178,205 shares — a large, confidence-signaling purchase disclosed to the SEC. SEC Filing
* Positive Sentiment: CIO Mitchell Young Williams acquired 51,511 shares at ~$3.03, raising his holdings to ~1,051,511 shares — another insider buy that supports management confidence. SEC Filing
* Positive Sentiment: Director Morgan Lee Lekstrom executed multiple purchases (including 41,000 and 23,000-share transactions at ~$3.13-$3.30), materially increasing her stake — another insider buy pattern reinforcing insider conviction. SEC Filing
* Neutral Sentiment: Press releases show closings of public offerings tied to the STEX ticker (announcements reporting $35M and $40.25M gross proceeds). If these refer to the same issuer, proceeds increase liquidity but also imply share issuance/dilution — impact depends on use of proceeds and whether this is the same corporate entity. Globe Newswire
* Negative Sentiment: Weiss Ratings initiated coverage with a “sell (d-)” rating, and MarketBeat shows an average analyst view of “Sell” — negative third‑party sentiment that can cap upside despite insider buying. Weiss Ratings
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings began coverage on shares of Biosig Technologies in a research report on Friday. They issued a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Biosig Technologies has a consensus rating of “Sell”.
Check Out Our Latest Analysis on STEX
Biosig Technologies Company Profile (
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
Read more on InsiderTrades.com
